Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomised Study